Vaxart
543 posts
- Vaxart today announced first quarter 2026 financial results. The Company will be hosting a fireside chat tomorrow, May 8 at 4:30 PM ET to answer frequently asked questions from stockholders. Read the full release: bit.ly/4wgdCKX #PillThatMovesTheNeedle $VXRT
- #Vaxart will report first quarter 2026 financial results on Thursday, May 7 with a fireside chat on May 8 at 4:30PM ET to answer stockholders' frequently asked questions. The live fireside chat can be accessed here: bit.ly/48DH7MC #PillThatMovesTheNeedle $VXRT
- Vaxart appoints James Breitmeyer to its Board of Directors. With more than 35 years of biopharmaceutical experience and eight FDA product approvals, James brings a wealth of knowledge and extensive drug development expertise to Vaxart’s Board. Read more: bit.ly/4vPgwWA
- Dr. Sean Tucker, our Founder and CSO, connected with @VaccineInsights to discuss how #Vaxart is reimagining vaccine delivery with oral tablet immunization, what led him to focus on oral vaccines and more. Read the interview: bit.ly/3QcuxNN $VXRT #PillThatMovesTheNeedle
- At @vaccinenation, Dr. James F. Cummings, our Chief Medical Officer, shared insights on next generation pandemic vaccine development and how Vaxart’s oral pill vaccine platform can improve how we address public health challenges. #WorldVaccineCongress #WVCDC #Vaxart
- $VXRT will host two upcoming conference calls: Full Year 2025 Financial Results Update: March 12 @ 4:30PM ET Vaxart Stockholder Virtual Fireside Chat: March 13 @ 4:30PM ET Call details including webcast links can be found here: bit.ly/4upnQb5 #PillThatMovesTheNeedle
- $VXRT today announced that members of the management team will present at the @Oppenheimer 36th Annual Healthcare Life Sciences Conference on Wednesday, February 25 at 4:00 PM ET. Register to join the live webcast: bit.ly/4aqbSpx













